Immunocore, a Milton Park, Oxfordshire, UK-based clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of medicines for cancer, infection and autoimmune disease, completed an over $130m Series B financing round.
The round was led by General Atlantic, with participation from CCB International, JDRF T1D Fund, Rock Springs Capital, Terra Magnum Capital Partners and WuXi AppTec’s Corporate Venture Fund, as well as Eli Lilly and Company and RTW Investments, and the Bill & Melinda Gates Foundation through conversion of its outstanding loan note.
The company intends to use the funds to further expand and accelerate its clinical stage pipeline of ImmTAX™ (Immune mobilising monoclonal TCRs Against Cancer, Infectious Diseases and Autoimmune) molecules that includes three oncology programs in MAGE-A4 (in collaboration with Genentech), NYESO-1 (in collaboration with GSK), and the lead program tebentafusp (IMCgp100), which is in pivotal clinical studies as a potential treatment for patients with metastatic uveal melanoma. The proceeds will allow the company to advance two wholly owned clinical-stage internal programs for chronic Hepatitis B and for PRAME, a target expressed in a wide range of tumors. This investment is also expected to accelerate its novel platform to treat autoimmunity, including type one diabetes (in collaboration with the JDRF T1D Fund), advance the TCR platform and expand its database of rich and novel targets.
Led by Bahija Jallal, Ph.D., Chief Executive Officer and Director, Immunocore is a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. The company’s most advanced programs are in oncology with a pipeline infectious and autoimmune diseases. Immunocore’s lead program, tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, and the Bill and Melinda Gates Foundation.
Immunocore also has offices in Conshohocken, Pennsylvania and Rockville, Maryland in the US.